Supplementary Figure 1 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
<p>Overall survival of ATM, BRCA2 mutant, and HRDother mPCs.</p>
Сохранить в:
Схожие документы
-
Supplementary Figure 2 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
по: Justin Hwang (15925675)
Опубликовано: (2025) -
Supplementary Figure 3 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
по: Justin Hwang (15925675)
Опубликовано: (2025) -
Supplementary Table 1 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
по: Justin Hwang (15925675)
Опубликовано: (2025) -
Supplementary Table 2 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
по: Justin Hwang (15925675)
Опубликовано: (2025) -
Supplementary Table 3 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
по: Justin Hwang (15925675)
Опубликовано: (2025)